Sao Paulo State University "Julio de Mesquita Filho", Faculdade de Ciências Farmacêuticas
Araraquara, São Paulo, 14800-903, Brazil
NCT Number: NCT03215043
First, it will be evaluated whether supplementation of eriocitrin reduces hyperglycemia and insulin resistance, significantly reducing the risk of diabetes. The effects of eriocitrin on the lipid profile, inflammatory, endothelial, hepatic and renal biomarkers will also be evaluated. It is expected that metabolic parameters that constitute risk factors for diabetes and associated chronic diseases are expected to be improved by supplementation with eriocitrin
Looking for future studies?
Notify Me30 year–59 year
All sexes
Interventional
Not applicable
Araraquara, São Paulo, 14800-903, Brazil
Volunteers will be invited to appear in a 12-hour fast to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview to confirm eligibility according to the inclusion and exclusion criteria. The collection of blood and the glycemic curves will be carried out next to a Laboratory of Clinical Analyzes, commercial, based in the city of Araraquara.
The sample number took into account variances on glycated hemoglobin with a type I error α = 0.05 and a type II error β = 0.2 (80% power) (Mohammad, 2015). The minimum sample size considering an approximately 20% dropout rate, should have 20 individuals per group.
In order to ensure adequate nutrition for the nutritional and energetic needs of volunteers, an individual food plan shall be prescribed, calculated according to the DRI equations. The volunteer will be asked to complete the Food Record for three days at the 3rd, 5th, 7th, 9th and 11th week. Data analysis of energy intake, macronutrients and micronutrients will be performed through the DietBox® . The anthropometric measurements will be performed before the intervention and in the 3rd, 5th, 7th, 9th and 11th week by Nutritionist. Four samples of 30mL of fasting blood each will be obtained before the intervention, in the 4th, 8th and 12th week in the Laboratory of Clinical Analyzes. The blood will be centrifuged to obtain the serum, which will be frozen at -80 ° C until subsequent biochemical analyzes.
Normality and homogeneity will be evaluated by Shapiro-Wilk test and Levine tests, respectively. The T test will be used to compare baseline time between groups. The two-way repeated-measures ANOVA will be used to compare changes within and between the eriocitrin and control groups over the 12-week period. P significant at ≤ 0.05.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
Time frame: 12 Weeks
mg/dL
Time frame: 12 Weeks
percentage
Time frame: 12 Weeks
µU/mL
Time frame: 12 Weeks
mg/dL
Time frame: 12 Weeks
mg/dL
Time frame: 12 Weeks
mg/dL
Time frame: 12 Weeks
mg/dL
Time frame: 12 Weeks
pg.mL
Time frame: 12 Weeks
pg.mL
Time frame: 12 Weeks
mg/dL
Time frame: 12 Weeks
U/L
Time frame: 12 Weeks
U/L
Time frame: 12 Weeks
U/L
Time frame: 12 Weeks
U/L
Time frame: 12 Weeks
Kg
Time frame: 12 Weeks
kg
Time frame: 12 Weeks
Percentage
Time frame: 12 Weeks
cm2
Thais Cesar
Other
Evaluation of Metabolic Parameters in Subjects With Intermediate Hyperglycemia Supplemented With Eriocitrin: A Parallel, Double-blind, Randomized, Placebo-controlled Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00063674
Adherence Interventions, Behavior
Palo Alto, California, United States
View Trial DetailsNCT03919877
Diabetes Mellitus, Diabetes Mellitus, Type 2
Stanford, California, United States
View Trial DetailsNCT07061496
Behavior, Glucose Intolerance
Nowshera, Pakistan
View Trial DetailsNCT04722354
Glucose Intolerance, Glucose Metabolism Disorders
Orlando, Florida, United States
View Trial Details